UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Investigational Drug Trial for Patients with Multiple Myeloma

Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment 

Participants in this research study have been diagnosed with multiple myeloma. This study is being done to see if the investigational drug (tabalumab) is safe and how well it works to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given and if tabalumab in combinsation with the drugs bortezomib and dexamethasone help people with myeloma. Researchers also want to investigate if the combination of drugs is safe and what side effects are associated with them.

Start Date
August 29, 2012
End Date
August 22, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Melanie Frees, 319-356-1228

Alkylating Agents ; Antineoplastic Agents ; Bortezomib ; Cancer ; Connective and Soft Tissue ; Dexamethasone ; IRB#201205703 ; Metastatic Soft Tissue Sarcoma ; Milhem ; Multiple Myeloma ; Neoplasms ; Phase 3 ; Phase III ; Refractory to Standard of Care Treatment ; Relapsed ; YONDELIS (trabectedin) ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.